| Name | Title | Contact Details |
|---|
Newmark is a Cheshire, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kernel is a human intelligence (HI) company. We`re a team of scientists and engineers on a mission to dramatically increase our quality of life and create a thriving humanity. We believe that starts with a renewed focus on human intelligence (HI). Machines of all kinds can help us along the way, but our vision is one in which we humans maintain and expand our authorial power. The advanced intelligence of tomorrow is a collaboration between the natural and the artificial. United, unheard of possibilities abound. We`re building off two decades of breakthrough research, working closely with private partners and scientists to get usable solutions in the hands of people everywhere. We’re starting with potential applications for patients with cognitive disorders.
NuVera Medical, Inc., a portfolio company of Shifamed, LLC., is a privately held company focused on the development of a novel imaging platform for use in a growing number of complex cardiovascular procedures.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.